Description
Created On: 2020-07-15
Record Count: 8
Primary Industries
- Cancer
- Medical
- Device
- Therapeutic
- Delivery
- Radiation
- Drugs
- Supply
- Disease
- Pharmaceuticals
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 264174
RadioGelâ„¢ is a brachytherapy device comprising highly insoluble Yttrium-90 particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors that cannot be treated effectively by any other means. It is designed for maximum safety: to deliver a high, pure-beta radiation dose to target (tumor) tissue, with comparatively small-to-negligible radiation doses to adjacent normal tissues, and with negligible radiation dose to any major organ or tissue in the body.
RadioGelâ„¢ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, one micron, yttrium-90 phosphate particles (“Y-90â€). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactively drops to 5% of its original value after ten days.
IPSCIO Record ID: 286475
As a result of this Amendment, the Company has agreed to revised terms regarding the license fee and royalty rate.
IPSCIO Record ID: 221773
The license granted shall be subject to any rights the Government of the United States of America may presently have or may assert in the future for any reason including, but not limited to, those rights set forth.
Licensor reserves the right to (i) practice the Patents for research, development and demonstration purposes for itself and others, (ii) nonexclusively license the Patents to nonprofit institutions that collaborate with Licensee for research, development, and demonstration purposes only, and (iii) license the Patents in fields not exclusively licensed herein.
Patent or Patents means the following patents, and all reissues, reexaminations, substitutes, and extensions thereof:
Issued Patents
Title: Stimulus Sensitive Gel with Radioisotope and Methods of Making (Licensee IPID 11505-E
Master Patent ID 1201)*
Country
Patent Number
Date Granted
U.S.
6,296,831
October 2, 2001
Title: Stimulus Sensitive Gel with Radioisotope and Methods of Making (Licensee IPID 11505-E
CON Master Patent ID 1204)*
Country
Patent Number
Date Granted
U.S.
6,869,588
March 22, 2005
Title: Stimulus Sensitive Gel with Radioisotope and Methods of Making (Licensee IPID 11505-E
Master Patent ID 1197)*
Country
Patent Number
Date Granted
Canada
2,327,325
January 24, 2006
Title: Thermogelling Biodegradable Aqueous Polymer Solution (Licensee IPID 12483-B Master Patent ID 1892)â€
Country
Patent Number
Date Granted
U.S.
6,841,617
January 11, 2005
Title: Thermogelling Oligopeptide Polymers (Licensee IPID 12483- B CIP Master Patent ID 1893) â€
Country
Patent Number
Date Granted
U.S.
7,087,244
August 8, 2006
Title: Thermogelling Biodegradable Aqueous Polymer Solution (Licensee IPID 12483-B Master Patent ID 1889) â€
Country
Patent Number
Date Granted
Canada
2,423,488
July 13, 2010
Title: Multiple Stimulus Reversible Hydrogels (Licensee IPID 12575-E Master Patent ID 1963)*
Country
Patent Number
Date Granted
U.S.
6,660,247
December 9, 2003
Title: Multiple Stimulus Reversible Hydrogels (Licensee IPID 12575-E CON Master Patent ID 4425)*
Country
Patent Number
Date Granted
U.S.
7,033,571
April 25, 2006
RadioGelâ„¢ device is a brachytherapy device comprising highly insoluble Yttrium-90 particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors that cannot be treated effectively by any other means. It is designed for maximum safety: to deliver a high, pure-beta radiation dose to target (tumor) tissue, with comparatively small-to-negligible radiation doses to adjacent normal tissues, and with negligible radiation dose to any major organ or tissue in the body.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.
IPSCIO Record ID: 1370
Licensor is willing to grant Licensee rights to the Licensor IP in the Territory with a limited field of use of intracavity radiation therapy (brachytherapy) of the brain (“Exclusive Field of Useâ€).
GliaSite® Radiation Therapy System (RTS) is for the treatment of brain cancer, i.e. primary and recurrent gliomas and metastic brain tumors. Specifically, the intended use of GliaSite® RTS is the management of surgically resectable brain tumors where adjuvant radiation therapy of the post-resection tissue bed is indicated.
IPSCIO Record ID: 1097
IPSCIO Record ID: 266765
The Wahl Patent Family shall mean U.S. Patents No. 6,251,362, and 6,022,521, including associated derivatives.
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are 'blood cancers' in the lymph nodes. They develop more frequently in older adults and in immunocompromised individuals. B-cell lymphomas include both Hodgkin's lymphomas and most non-Hodgkin lymphomas.
IPSCIO Record ID: 1054
Its intended use is as a means of micro-arterial brachytherapy in the treatment of soft tissue cancer tumors in the liver. Soft tissue tumors are connected to the blood supply and this kind of therapy is administered through the blood supply system. Soft tissue tumors are among the most difficult forms of cancer to treat.
IPSCIO Record ID: 3837
Under a different configuration, the device is designed as an external beam radiation treatment unit to produce thermal neutrons that are essential for gadolinium neutron capture therapy (GNCT), a type of external beam radiation therapy used to treat certain tumorous cancers located in or near critical organs. Under GNCT, the element gadolinium is transported to a patient’s cancerous tumor and irradiated with an external beam of thermal neutrons which destroys the tumor without damage to external healthy tissue.